Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2008-07-29
2008-07-29
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S001110, C424S001650
Reexamination Certificate
active
07404963
ABSTRACT:
The present invention provides adjuvants, vaccines and related methods that are useful in eliciting immune responses, particularly immune responses against tumor antigens. We discovered that flagellin is capable of inhibiting tolerance when it is administered in conjunction with a tolerogenic antigen. This effect is likely mediated by the ability of flagellin to induce IL-12 while keeping IL-10 levels low. Furthermore, flagellin can be provided in an extended-releasing manner by using a flagellin-expressing cell. Preferably, the flagellin-expressing cell is treated such that it is no longer capable of replicating, yet retaining the ability to express flagellin, such as by lethal irradiation.
REFERENCES:
patent: 6130082 (2000-10-01), Majarian et al.
patent: 2003/0044429 (2003-03-01), Aderem et al.
patent: 2003/0170756 (2003-09-01), Berd
patent: 2005/0257280 (2005-11-01), Akira
patent: 2006/0002941 (2006-01-01), Mahairas
Sbrogio-Almeida, M.E., Mosca, T., Massis, L.M., Abrahamsohn, I.A., and Ferreira, L.C.S. Host and bacterial factors affecting induction of immune responses to flagellin expressed by attenuatedSalmonellavaccine strains. 2004. Infection and Immunity, vol. 72 No. 5, pp. 2546-2555.
Sfondrini, L., Rossini, A., Besusso, D., Merlo, A., Tagliabue, E., Menard, S., and Balsari, A. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. 2006. Journal of Immunology, vol. 176. pp. 6624-6630.
Pawelek, J.M., Low, K.B., and Bermudes, D. Tumor-targetedSalmonellaas a novel anticancer vector. 1997. Cancer Research, vol. 57, pp. 4537-4544.
Mitchell, M.S. Cancer vaccines, a critical review—Part I. 2001. Current Opinion in Investigational Drugs. vol. 3 No. 1, pp. 140-149.
Margulis, L. Undulipodia, flagella and cilia. Biosystems, 1980, vol. 12, pp. 105-108 (abstract only).
Berg, J.M., Tymoczko, J.L., Stryer, L., and Clarke, N.D., eds. Biochemistry. 5thedition, W.H. Freeman and Company, 2002. pp. 34-35 and 967.
Borrello, I., et al. (1999). A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther. 10(12):1983-1991.
Bretscher, P., and Cohn, M. (1970). A theory of self-nonself discrimination. Science. 169(950):1042-1049.
Cheng, F., et al. (2003). A critical role for Stat3 signaling in immune tolerance. Immunity. 19(3):425-436.
Ibrahim, G.F., et al. (1985). Method for the isolation of highly purifiedSalmonella flagellins. J Clin Microbiol. 22(6):1040-1044.
Jenkins, M.K., and Schwartz, R.H. (1987). Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 165(2):302-319.
Levitsky, H.I., et al. (1994). In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 179(4):1215-1224.
McSorley, S.J., et al. (2002). Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol. 169(7):3914-3919.
Mizel, S.B., et al. (2003). Identification of a sequence in human toll-like receptor 5 required for the binding of gram-negative flagellin. J Biol Chem. 278(26):23624-23629.
Murthy, K.G., et al. (2004). Identification of conserved domains inSalmonella muenchenflagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro. J Biol Chem. 279(7):5667-5675.
Smith, K.D., et al. (2003). Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol. 4(12):1247-1253.
Didierlaurent, A., et al. (2004). Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol. 172(11):6922-6930.
Hayashi, F., et al. (2001). The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature. 410(6832):1099-1103.
Eaves-Pyles, et al., “SalmonellaFlagellin-Dependent Proinflammatory Responses are Localized to the Conserved Amino and Carobxyl Regions of the Protein,”The Journal of Immunology, 167: 7009-7016 (2001).
Sotomayor Eduardo M.
Suarez Ildefonso
Fish & Richardson P.C.
Gussow Anne M
Helms Larry R.
The University of South Florida
LandOfFree
Flagellin-based adjuvants and vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Flagellin-based adjuvants and vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Flagellin-based adjuvants and vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2745216